The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35
Listen now
Description
In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.
Episode 35 links:
Visit TPM E35 for highlights and links from this episode >
Learn more about Genialis™ krasID >
New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients >
More Episodes
Published 04/12/24
Today we turn the mic around, as our guest Adam Stasio hosts an excellent podcast of his own. Adam’s day job, however, is running SciMed, a boutique life sciences software development company. Adam and Genialis CEO Rafeal Rosengarten discuss the state of scientific software, the importance of...
Published 12/14/23
Our guest today is Dr. Ashley Zehnder, co-founder and CEO of Fauna Bio. Fauna is a revolutionary young biotech company using comparative genomics of an array of non-traditional mammalian models to discover new therapeutic opportunities for people. What do ground squirrels have to do with treating...
Published 10/27/23
Links
Twitter
Facebook
Instagram
Patreon
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
